MedTrace Logo

Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome

NCT00114127 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2014-06-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder.

Conditions

  • Anxiety Disorder

Interventions

DRUG

Duloxetine

60 mg duloxetine 1x per day

DRUG

Duloxetine

60 mg duloxetine 1x per day + 60mg duloxetine 1x per day

DRUG

Placebo

60mg placebo 1x per day

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Naomi M Simon, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2008-11-30
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00114127 on ClinicalTrials.gov